Loading...
XNAS
NIVF
Market cap13mUSD
Jul 09, Last price  
1.31USD
1D
-1.50%
1Q
-78.57%
IPO
-97.57%
Name

NewGenIvf Group Ltd

Chart & Performance

D1W1MN
XNAS:NIVF chart
P/E
1.35
P/S
2.81
EPS
0.97
Div Yield, %
Shrs. gr., 5y
Rev. gr., 5y
%
Revenues
5m
-13.01%
4,118,0005,944,0005,136,1535,433,0004,726,433
Net income
10m
P
-533458,667130,193-525,0009,879,408
CFO
-11m
L+32.21%
1,433,000-527,123-1,790,839-8,264,074-10,926,056

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

NewGenIvf Group Limited operates as an investment holding company specializing in providing assisted reproductive technologies (ART) for couples and individuals seeking fertility solutions. The company extends its operations across Thailand, Cambodia, Hong Kong, and Kyrgyzstan. Its comprehensive suite of fertility treatments includes fundamental procedures such as in vitro fertilization (IVF), intracytoplasmic sperm injection (ICSI), and embryo culture. NewGenIvf also offers crucial diagnostic and preparatory services like hormonal blood tests, screenings for infectious diseases, chromosome analysis, and hysteroscopy. Additionally, the company provides specialized sperm services, encompassing analysis, sorting, washing, and cryopreservation, alongside oocyte (egg) freezing. Beyond these core medical services, NewGenIvf facilitates surrogacy arrangements, offering essential ancillary care for surrogate mothers, including routine health check-ups, nutritional supplements, and prescribed medications. To further enhance the patient journey, the company delivers a range of supplementary services such as dietary guidance, psychological counseling, acupuncture, and professional translation interpreters. These specialized medical and support services are delivered through the company's network of dedicated clinics. Founded in 2010, NewGenIvf Group Limited is headquartered in Bangkok, Thailand.
URL
IPO date
Feb 15, 2022
Employees
Domiciled in
SG
Incorporated in
VG

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT